Depression. Major depressive disorder, single episode, moderate
Conditions
Interventions
Intervention 1: Placebo Group in which, patients (n=40) will receive placebo tablets twice a day, for 8 weeks. Intervention 2: Silymarin Group in which, patients (n=40) will receive silymarin 140 mg,
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients with moderate depression Being 20-50 years old Patient consent to participate in the study Not having specific physical (e.g. cancer, Acquired immunodeficiency syndrome (AIDS), Multiple Sclerosis (MS)) or mental illness Not having allergic to silymarin Not being pregnant/breast feeding
Exclusion criteria
Exclusion criteria: Lack of patient cooperation in silymarin consumption Having allergic reaction or intolerable side effect caused by silymarin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Beck Depression Inventory (BDI) questionnaire. Timepoint: Before treatment (day 0) and at the end of weeks 4 and 8 after starting treatment. Method of measurement: Completion of the questionnaire by patient or researcher.;General Health Questionnaire (GHQ). Timepoint: Before treatment (day 0) and at the end of weeks 4 and 8 after starting treatment. Method of measurement: Completion of the questionnaire by patient or researcher. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaedeh Kamrani
Mashhad University of Medical Sciences
Outcome results
None listed